Diligence memo · auto-generated · as of July 2, 2026
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Hepion Pharmaceuticals, Inc. operates in Pharmaceuticals, based in EDISON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Hepion Pharmaceuticals, Inc. has raised $46M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2022-11-04.
Most recent recorded round closed around 2024-07-19.
Valuation (modeled)modeled
Provath models Hepion Pharmaceuticals, Inc. at approximately $20M (range $6.1M–$35M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.15× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 23 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 80% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 27% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.